User profiles for John A Snowden

Professor John Snowden

Sheffield Teaching Hospitals NHS Foundation Trust & University of Sheffield, Sheffield, UK
Verified email at ebmt.org
Cited by 18329

[PDF][PDF] Guidelines for the diagnosis and management of adult aplastic anaemia

…, G Mufti, JA Snowden… - British journal of …, 2016 - redbook.streamliners.co.nz
… Mufti,7 John A. Snowden,8 Sujith Samarasinghe,9 Anna Wood, BCSH Task Force
Member10 and Judith CW Marsh7 on behalf of the British Society for Standards in Haematology …

[HTML][HTML] Hematopoietic cell transplantation and cellular therapy survey of the EBMT: monitoring of activities and trends over 30 years

…, M Mohty, R Peffault de Latour, JA Snowden… - Bone marrow …, 2021 - nature.com
Numbers of Hematopoietic cell transplantation (HCT) in Europe and collaborating countries
continues to rise with 48,512 HCT in 43,581 patients, comprising of 19,798 (41%) allogeneic …

[HTML][HTML] Indications for haematopoietic cell transplantation for haematological diseases, solid tumours and immune disorders: current practice in Europe, 2022

JA Snowden, I Sánchez-Ortega… - Bone marrow …, 2022 - nature.com
For over two decades, the EBMT has updated recommendations on indications for haematopoietic
cell transplantation (HCT) practice based on clinical and scientific developments in …

Azacitidine augments expansion of regulatory T cells after allogeneic stem cell transplantation in patients with acute myeloid leukemia (AML)

…, M Raghavan, M Cook, JA Snowden… - Blood, The Journal …, 2012 - ashpublications.org
Strategies that augment a GVL effect without increasing the risk of GVHD are required to
improve the outcome after allogeneic stem cell transplantation (SCT). Azacitidine (AZA) up-…

[PDF][PDF] Guidelines for the diagnosis and management of multiple myeloma 2011

JM Bird, RG Owen, S d'Sa, JA Snowden… - British journal of …, 2011 - iacld.com
… ’ and ‘Supportive care in multiple myeloma 2011’ (Snowden et al 2011). They are designed
to … of peripheral neuropathy is described in detail in the supportive care guideline (Snowden

Inhibiting Dickkopf‐1 (Dkk1) removes suppression of bone formation and prevents the development of osteolytic bone disease in multiple myeloma

…, HR Evans, JA Snowden… - Journal of Bone and …, 2009 - academic.oup.com
Multiple myeloma (MM) is associated with the development of osteolytic bone disease,
mediated by increased osteoclastic bone resorption and impaired osteoblastic bone formation. …

[HTML][HTML] The challenge of COVID-19 and hematopoietic cell transplantation; EBMT recommendations for management of hematopoietic cell transplant recipients, their …

…, J Murray, R Peffault de Latour, JA Snowden… - Bone marrow …, 2020 - nature.com
The new coronavirus SARS-CoV-2 has rapidly spread over the world causing the disease
by WHO called COVID-19. This pandemic poses unprecedented stress on the health care …

Indications for haematopoietic stem cell transplantation for haematological diseases, solid tumours and immune disorders: current practice in Europe, 2019

…, A Nagler, R Peffault de Latour, JA Snowden… - Bone marrow …, 2019 - nature.com
This is the seventh special EBMT report on the indications for haematopoietic stem cell
transplantation for haematological diseases, solid tumours and immune disorders. Our aim is to …

Effect of nonmyeloablative hematopoietic stem cell transplantation vs continued disease-modifying therapy on disease progression in patients with relapsing-remitting …

…, R Balabanov, J Burman, B Sharrack, JA Snowden… - Jama, 2019 - jamanetwork.com
Importance Hematopoietic stem cell transplantation (HSCT) represents a potentially useful
approach to slow or prevent progressive disability in relapsing-remitting multiple sclerosis (MS…

[HTML][HTML] Management of adults and children undergoing chimeric antigen receptor T-cell therapy: best practice recommendations of the European Society for Blood …

…, R Saccardi, F Sanchez-Guijo, JA Snowden… - …, 2020 - ncbi.nlm.nih.gov
Chimeric antigen receptor (CAR) T cells are a novel class of anti-cancer therapy in which
autologous or allogeneic T cells are engineered to express a CAR targeting a membrane …